Downregulation of lncRNA PVT1 expression inhibits proliferation and migration by regulating p38 expression in prostate cancer

Wan, Bo; Wu, Haoyue; Lv, Daojun; Zhou, Xumin; Zhong, Lintao; Lei, Bin; Zhang, Shou‐Bo; Mao, Xiangming

doi:10.3892/ol.2018.9305

Cited by 22 publications

(26 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Located at the 8q24 chromosomal region, the long nonprotein-coding gene PVT1 has been shown to be overexpressed in various cancers including PCa, breast, pancreatic, lung, and gastric cancers. Downregulation of expression of the long noncoding RNA (lncRNA) from PVT1 inhibits proliferation and migration by regulating p38 expression in PCa [19]. Increasing evidence has shown the important role of lncRNAs in many different biological processes [23][24][25][26][27][28][29][30][31].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells

Pal

Huaman

Levine

et al. 2019

Genes

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common non-cutaneous cancer and second leading cause of cancer-related death for men in the United States. The nonprotein coding gene locus plasmacytoma variant translocation 1 (PVT1) is located at 8q24 and is dysregulated in different cancers. PVT1 gives rise to several alternatively spliced transcripts and microRNAs. There are at least twelve exons of PVT1, which make separate transcripts, and likely have different functions. Here, we demonstrate that PVT1 exon 9 is significantly overexpressed in PCa tissues in comparison to normal prostate tissues. Both transient and stable overexpression of PVT1 exon 9 significantly induced greater prostate epithelial cell migration, as well as increased proliferation and corresponding proliferating cell nuclear antigen (PCNA) expression. Notably, implantation into mice of a non-tumorigenic prostate epithelial cell line stably overexpressing PVT1 exon 9 resulted in the formation of malignant tumors. Furthermore, PVT1 exon 9 overexpression significantly induced castration resistance. Consequently, PVT1 exon 9 expression is important for PCa initiation and progression, and holds promise as a therapeutic target in PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recent studies have identified PVT1 as being procarcinogenic and have shown that PVT1 amplification increases the risk of PCa incidence [5,9,19]. We previously demonstrated that the transcript from exon 9 of PVT1 may be involved in PCa, but the underlying molecular mechanisms were unknown [7].…”

Section: Introductionmentioning

confidence: 96%

Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells

Pal

Huaman

Levine

et al. 2019

Genes

View full text Add to dashboard Cite

show abstract

“…Data from many sources suggest that PVT1 is a major contributor to the development of prostate cancer (81,82). A CCK-8 (Cell Counting Kit-8) assay assessment of the effect of PVT1 downregulation in PC3 and DU145 cells showed an inhibition of cell proliferation (83). Confirming this effect in the same study, PVT1 downregulation also reduced the size of tumors in mice.…”

Section: Pvt1 In Prostate Cancermentioning

confidence: 54%

Oncogenic Role of PVT1 and Therapeutic Implications

et al. 2020

View full text Add to dashboard Cite

PVT1, a long non-coding RNA has been implicated in a variety of human cancers. Recent advancements have led to increasing discovery of the critical roles of PVT1 in cancer initiation and progression. Novel insight is emerging about PVT1's mechanism of action in different cancers. Identifying and understanding the variety of activities of PVT1 involved in cancers is a necessity for the development of PVT1 as a diagnostic biomarker or therapeutic target in cancers where PVT1 is dysregulated. PVT1's varied activities include overexpression, modulation of miRNA expression, protein interactions, targeting of regulatory genes, formation of fusion genes, functioning as a competing endogenous RNA (ceRNA), and interactions with MYC, among many others. Furthermore, bioinformatic analysis of PVT1 interactions in cancers has aided understanding of the numerous pathways involved in PVT1 contribution to carcinogenesis in a cancer type-specific manner. However, these recent findings show that there is much more to be learned to be able to fully exploit PVT1 for cancer prognostication and therapy. In this review, we summarize some of the latest findings on PVT1's oncogenic activities, signaling networks and how targeting these networks can be a strategy for cancer therapy.

show abstract

“…LncRNA SNHG7 can affect miR-503/Cyclin D1 pathway then regulate the viability and cycle progression of PC cells (32). The down-regulation of lncRNA PVT1 can regulate p38 expression then decrease PC cells metastasis (33). In addition, it has been reported that lncRNA HOTAIR and MALAT1 affect transcriptional regulation in PC cells induced by estrogen (34).…”

Section: Discussionmentioning

confidence: 99%

The Inhibition of Long Non-Coding RNA CAR10 and The Regulation of miR-203 Expression Suppresses Cell Viability and Induces Cell Apoptosis in Prostate Cancer

Zhang¹,

Chen²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Prostate cancer (PC) is one of the most common malignant tumors. Recently, it has been reported that long noncoding RNAs (lncRNAs) play key roles in tumor progression. Studies have revealed that long non-coding RNA CAR10 (CAR10) can regulate tumor cell behaviors through sponging miR-203. In this study, we examined the effects of CAR10 in PC cells. Methods: Firstly, real time-quantitative polymerase chain reaction (qRT-PCR) was used to explore CAR10 expression in tumor tissues, peripheral blood of PC patients, and PC cells. We used the dual-luciferase reporter gene assay to analyze the relationship between CAR10 and miR-203. Moreover, flow cytometry, MTT assay, and western blot assay were used to determine cell apoptosis, cell viability, and apoptosis-related protein expression. Results: The results showed that CAR10 expression was remarkably higher in PC samples compared with that of control, and CAR10 regulated miR-203 negatively in PC cells. The qRT-PCR results also showed that miR-203 expression was significantly decreased in PC samples. Moreover, knockdown of CAR10 inhibited PC cell viability and promoted cleaved caspase-3 expression but induced PC cell apoptosis and, reduced pro-caspase-3 expression; miR-203 inhibitor reversed these effects. Conclusion: Our study found that CAR10 is a potential oncogene in PC and suggests that CAR10 inhibition could inhibit PC cell viability but promote PC cell apoptosis through regulating miR-203 expression. Our results show that CAR10 is a potential target for the treatment of PC.

show abstract

Downregulation of lncRNA PVT1 expression inhibits proliferation and migration by regulating p38 expression in prostate cancer

Cited by 22 publications

References 40 publications

Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells

Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells

Oncogenic Role of PVT1 and Therapeutic Implications

The Inhibition of Long Non-Coding RNA CAR10 and The Regulation of miR-203 Expression Suppresses Cell Viability and Induces Cell Apoptosis in Prostate Cancer

Contact Info

Product

Resources

About